75 related articles for article (PubMed ID: 2178128)
1. Biological activity of diethyldithiocarbamate (Ditiocarb, Imuthiol) in an animal model of retrovirus-induced immunodeficiency disease and in clinical trials in patients with HIV infection. The Ditiocarb Study Group.
Hersh EM; Funk CY; Petersen EA; Mosier DE
Dev Biol Stand; 1990; 72():355-63. PubMed ID: 2178128
[TBL] [Abstract][Full Text] [Related]
2. Effective therapy of the LP-BM5 murine retrovirus-induced lymphoproliferative immunodeficiency disease with diethyldithiocarbamate.
Hersh EM; Funk CY; Ryschon KL; Petersen EA; Mosier DE
AIDS Res Hum Retroviruses; 1991 Jun; 7(6):553-61. PubMed ID: 1657074
[TBL] [Abstract][Full Text] [Related]
3. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study.
Hersh EM; Brewton G; Abrams D; Bartlett J; Galpin J; Gill P; Gorter R; Gottlieb M; Jonikas JJ; Landesman S
JAMA; 1991 Mar; 265(12):1538-44. PubMed ID: 1671884
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, randomized, placebo-controlled study of ditiocarb (Imuthiol) in human immunodeficiency virus-infected asymptomatic and minimally symptomatic patients. The HIV87 Study Group.
AIDS Res Hum Retroviruses; 1993 Jan; 9(1):83-9. PubMed ID: 8094001
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic properties of sodium diethyldithiocarbamate: its role as an inhibitor in the progression of AIDS.
Sunderman FW
Ann Clin Lab Sci; 1991; 21(1):70-81. PubMed ID: 1849385
[TBL] [Abstract][Full Text] [Related]
6. Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS.
Stadler I; Chadha KC; Nakeeb S; Toumbis C; Butsch J; Mathur N; Munschauer F; Vladutiu A; Satchidanand SK; Ambrus JL
J Pharmacol Exp Ther; 1994 Jan; 268(1):10-3. PubMed ID: 8301544
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS.
Green KA; Noelle RJ; Green WR
Virology; 1998 Feb; 241(2):260-8. PubMed ID: 9499800
[TBL] [Abstract][Full Text] [Related]
8. Dose response and timing effects in the therapy of the LP-BM5 murine retrovirus-induced lymphoproliferative immunodeficiency disease with diethyldithiocarbamate.
Hersh EM; Funk CY; Petersen EA; Ryschon KL; Mosier DE
Int J Immunopharmacol; 1993 Feb; 15(2):137-43. PubMed ID: 8385652
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
[TBL] [Abstract][Full Text] [Related]
10. HIV infection and AIDS.
Lloyd A
P N G Med J; 1996 Sep; 39(3):174-80. PubMed ID: 9795558
[TBL] [Abstract][Full Text] [Related]
11. Treatment of the murine, retrovirus-induced lymphoproliferative immunodeficiency disease (LP-BM5) in C57BL/10 mice with the immunomodulator Imexon.
Funk CY; Eisman J; Hersh EM
AIDS Res Hum Retroviruses; 1992 May; 8(5):633-8. PubMed ID: 1515214
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection.
Kaplan CS; Petersen EA; Yocum D; Hersh EM
Life Sci; 1989; 45(22):iii-ix. PubMed ID: 2557513
[TBL] [Abstract][Full Text] [Related]
13. Effect of selenium supplementation on mice infected with LP-BM5 MuLV, a murine AIDS model.
Chen C; Zhou J; Xu H; Jiang Y; Zhu G
Biol Trace Elem Res; 1997; 59(1-3):187-93. PubMed ID: 9522061
[TBL] [Abstract][Full Text] [Related]
14. Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection.
Lang JM; Touraine JL; Trepo C; Choutet P; Kirstetter M; Falkenrodt A; Herviou L; Livrozet JM; Retornaz G; Touraine F
Lancet; 1988 Sep; 2(8613):702-6. PubMed ID: 2901566
[TBL] [Abstract][Full Text] [Related]
15. [Cardiac involvement in HIV infection: a prospective, multicenter clinical and echocardiographic study].
Mirri A; Rapezzi C; Iacopi F; Ortolani P; Binetti G; Fabbri M; Ortolani P; Zauli T; Pintori C; Baroni M
Cardiologia; 1990 Mar; 35(3):203-9. PubMed ID: 2245421
[TBL] [Abstract][Full Text] [Related]
16. [Clinical manifestations of acquired immunologic deficiency syndrome (AIDS)].
Goebel FD
Acta Med Austriaca; 1987; 14(1):1-4. PubMed ID: 3475926
[TBL] [Abstract][Full Text] [Related]
17. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
Vial PA; Ferreccio C; Abarca K; Ortiz E; Noriega M; Pérez C; Labarca J; Torres M; Ferrés M; González C; Acuña G
Rev Med Chil; 1996 May; 124(5):525-35. PubMed ID: 9035503
[TBL] [Abstract][Full Text] [Related]
18. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Mayhew C; Oakley O; Piper J; Hughes NK; Phillips J; Birch NJ; Elford HL; Gallicchio VS
Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1019-29. PubMed ID: 9449534
[TBL] [Abstract][Full Text] [Related]
19. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
20. Animal models for HIV infection and AIDS: memorandum from a WHO meeting.
Bull World Health Organ; 1988; 66(5):561-74. PubMed ID: 2850118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
